PARKINSON S MEDICATION

Similar documents
Parkinson s disease. Information for patients and carers. The Leeds Teaching Hospitals NHS Trust

Motor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University

History Parkinson`s disease. Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson

parts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to

Medications used to treat Parkinson s disease

Drug Therapy of Parkinsonism. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Appendix 2: Admissions checklists for people with Parkinson s

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology

Parkinson s Disease Medications: Professionals Edition

Commonly encountered medications and their side effects - what the generalist needs to know

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology

Best Medical Treatments for Parkinson s disease

An Overview of Parkinson s Medication used in Multiple System Atrophy

Optimizing Clinical Communication in Parkinson s Disease:

Parkinson's Disease and how you can make a difference with medication

An Overview of Parkinson s Medication used in Multiple System Atrophy

ACUTE MANAGEMENT OF PARKINSON S PATIENTS WHO ARE NIL BY MOUTH (NBM) OR WHO HAVE A COMPROMISED SWALLOW NHS LANARKSHIRE PARKINSON S TEAM

Margo J Nell Dept Pharmacology

Treatment of Parkinson s Disease: Present and Future

Communicating About OFF Episodes With Your Doctor

New Medicines Committee Briefing July 2011

10th Medicine Review Course st July Prakash Kumar

Treatment of Parkinson s Disease and of Spasticity. Satpal Singh Pharmacology and Toxicology 3223 JSMBS

Re-Submission. Scottish Medicines Consortium. rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd.

MANAGEMENT OF PATIENTS WITH PARKINSON S DISEASE WHO ARE NIL BY MOUTH OR WITH A COMPROMISED SWALLOW

Objectives. Emerging Treatments in Parkinson s s Disease. Pathology. As Parkinson s progresses it eventually affects large portions of the brain.

Parkinson s Disease Current Treatment Options

DRUG TREATMENT OF PARKINSON S DISEASE. Mr. D.Raju, M.pharm, Lecturer

Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE

Summary of Patient < 3y at Visit 11 (90 months)

PARKINSON S DISEASE. Nigrostriatal Dopaminergic Neurons 5/11/16 CARDINAL FEATURES OF PARKINSON S DISEASE. Parkinson s disease

Drug Management of Parkinsonism. By Prof. Mohammad Saleh M. Hassan PhD. (Pharma); MSc. (Ped.); MHPE (Ed.)

PD ExpertBriefings: Parkinson s Medications: Today and Tomorrow Led By: Cynthia L. Comella, M.D., F.A.A.N.

2-The age at onset of PD is variable, usually between 50 and 80 years, with a mean onset of 55 years (1).

Parkinson s Disease. Gillian Sare

Parkinson s disease Therapeutic strategies. Surat Tanprawate, MD Division of Neurology University of Chiang Mai

Clinical Guideline for the management of inpatients with Parkinson s disease

Management of Parkinson s Disease in Primary and Secondary care for patients with compromised swallow or those patients deemed Nil By Mouth.

Drugs Affecting the Central Nervous System

Movement Disorders: A Brief Overview

05-Nov-15. Impact of Parkinson s Disease in Australia. The Nature of Parkinson s disease 21st Century

Acute management of in-patient Parkinson s Disease patients

Continuous dopaminergic stimulation

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

Guidelines for acute treatment of patients with Parkinson s disease including those who are nil by mouth

DRUGS THAT ACT IN THE CNS

The symptoms of the Parkinson s disease may vary from person to person. The symptoms might include the following:

Scottish Medicines Consortium

Parkinson s Pharmacology

Anticholinergics. COMT* Inhibitors. Dopaminergic Agents. Dopamine Agonists. Combination Product

Parkinson s disease: diagnosis and current management

Evaluation and Management of Parkinson s Disease in the Older Patient

Program Highlights. Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone Medical Center New York, New York

Advanced Therapies for Motor Symptoms in PD. Matthew Boyce MD

Medication Management & Strategies When the levodopa honeymoon is over

The Shaking Palsy of 1817

Dorset Medicines Advisory Group SHARED CARE GUIDELINES FOR PRESCRIBING ENTACAPONE (INCLUDING IN COMBINATION) OR OPICAPONE IN PARKINSON S DISEASE

Drugs for Parkinson s Disease

PD: Key Treatment Considerations

Presented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn

Faculty. Joseph Friedman, MD

Recent Advances in the cause and treatment of Parkinson disease. Anthony Schapira Head of Dept. Clinical Neurosciences UCL Institute of Neurology UCL

Final Appraisal Report. ) for the treatment of idiopathic Parkinson s disease. Ropinirole prolonged-release (Requip XL. GlaxoSmithKline UK

9/26/18. Objectives. Disclosures. Parkinson s Disease Update Clinical and Operational Considerations

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

Drugs used in Parkinsonism

Parkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O.

What s new for diagnosing and treating Parkinson s Disease?

Parkinson s Disease Update. Colleen Peach, RN, MSN, FNP Movement Disorders Clinic Emory University School of Medicine March 7, 2015

Parkinson s Well-Being Map TM

Parkinson s Disease. Sirilak yimcharoen

8/28/2017. Behind the Scenes of Parkinson s Disease

The Role of Pharmacists in Treating & Managing Parkinson s Disease Author: Mary Jo Carden, RPh, JD Principal, Carden Associates

Parkinson s Disease Prescribing Guidelines for use in Primary and Secondary Care

Parkinson's Disease KP Update

Key Concepts and Issues in Parkinson s Disease in 2016

A Review on Parkinson s Disease: Its Surgical Inventional Therapies, Pathophysiology and Treatment

Neurodegenerative diseases

475 GERIATRIC PSYCHOPHARMACOLOGY (p.1)

XADAGO (safinamide) oral tablet

Novel approaches to the pharmacological treatment of Parkinson s disease. Peter Jenner King s College UK

CE Prn. Pharmacy Continuing Education from WF Professional Associates ABOUT WFPA LESSONS TOPICS ORDER CONTACT PHARMACY EXAM REVIEWS

Welcome and Introductions

WHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019

TRANSPARENCY COMMITTEE OPINION. 18 March 2009

Clinical Features and Treatment of Parkinson s Disease

Early Treatment Options When to start, what with, and why?

A Review on Parkinson s Disease: Its Pathophysiology, Treatment and Surgery

Pal Riba, M.D., Ph.D. Department of Pharmacology and Pharmacotherapy Semmelweis University, Budapest, Hungary November 7, 2017

ANTIPARKINSONIAN DRUGS. DRUGs ACT ON CNS (Pharmacology) Unit-5(8)

Cardinal Features of Parkinson s. Management of Parkinson s Disease. Drug Induced Parkinson s. Other Parkinson s Symptoms.

THE ART OF MEDICATION MANAGEMENT IN PARKINSON S DISEASE

What is the best medical therapy for early Parkinson's disease? Medications Commonly Used for Parkinson's Disease

Prior Authorization with Quantity Limit Program Summary

Parkinson s Disease. Graham A. Glass, MD. Assistant Professor of Neurology University of California San Francisco

Dr Barry Snow. Neurologist Auckland District Health Board

Medicines Management and the Unwell Parkinson s Patient

Guideline for the Management of Parkinson s Disease Medication Trust Reference B26/2017

GUIDELINES FOR THE MANAGEMENT OF PATIENTS WITH PARKINSON S DISEASE (PD) ADMITTED TO HOSPITAL. Reviewer s Name, Title & address:

Transcription:

PARKINSON S MEDICATION

History 1940 50 s Neurosurgeons operated on basal ganglia. Improved symptoms. 12% mortality 1960 s: Researchers identified low levels of dopamine caused Parkinson s leading to development of Levodopa. 1968: Levodopa pills available for use. 1970: Bromocriptine & MAO-B inhibitor deprenyl 1980 s: Pergolide, selegiline 1980/90 s: Deep brain surgery refined. 1990 s: Genetic defects implicated in Parkinson s discovered. 1997: Pramipexole & Ropinirole 1998: Tolcapone & Entacapone 2000 >: Stem cell biology suggetsed new therapies would come soon as yet not emerged. 2006: MAO-B inhibitor Rasagaline. Not SMC approved in Scotland 2007: Rotigotine patch

Substantia nigra

What is Parkinson s disease?

The problem with Parkinson s

SYNAPSE

Peaks & Troughs

Wearing-off is thought to result from degeneration of nigrostriatal neurons and sub-therapeutic delivery of Levodopa Dopamine receptor state Normal Activated Unactivated Striatum Activated PD (untreated) Substantia nigra Unactivated Nigrostriatal neurons degenerate Conventional levodopa Activated Unactivated * Conventional levodopa *Levodopa dose; PD=Parkinson's disease Olanow et al. Lancet Neurol 2006;5(8):677

DRUG CHOICE PREFERENCE OF CONSULTANT PRESCRIBED TO SUIT EACH INDIVIDUAL AGE COGNITIVE STATE

DRUG CHOICE DOPAMINE AGONISTS V L-DOPA

DRUG MANAGEMENT AIMS TO RESTORE BALANCE BETWEEN NEUROTRANSMITTERS DOPAMINERGIC: Levodopa Co-Careldopa Careldopa (Sinemet), Co-Beneldopa (Madopar) DOPAMINE AGONISTS: Ropinirole, Pramipexole Rotigotine patch Apomorphine injection / infusion CATECHOL-O-METHYL TRANSFERASE (COMT) INHIBITORS: Entacapone MONOAMINE OXIDASE B INHIBITORS: Selegiline Rasagaline Antimuscarinic: Orphenadrine, Procyclidine (Rarely used)

LEVODOPA + DECARBOXYLASE INHIBITOR Prescribed since 1960 s Still Gold standard drug for Parkinson s Most effective for: Stiffness rigidity Slowness - bradykinesia

MADOPAR (co-beneldopa) Benserazide hcl (1 part) / Levo-dopa (4 parts) eg 12.5 / 50 = 62.5 25 / 100 = 125 50 / 200 = 250 Capsules Dispersible CR : 125 (70% bio-availability)

SINEMET (Co- Careldopa) Carbidopa / Levodopa eg: 12.5 / 50 = 62.5 10 / 100 = 110 25 / 100 = 125 (PLUS) 25 / 250 = 275 Tablets Half SINEMET CR SINEMET CR

Entacapone / STALEVO (combination Sinemet & Entacapone) How COMT inhibitors work

DOPAMINE AGONIST S Non Ergot Ropinirole (3-24mg) Pramipexole (max 3.3mg base). Rotigotine Apomorphine (s/c only) Nausea Drowsiness Leg oedema Abdominal pain Hypotension ADJUNCT: Hallucinations Confusion Dyskinesia

ROPINIROLE Max 24mg daily

MIRAPEXIN (Pramipexole) IMMEDIATE RELEASE MAX DAILY: 3.3MG(BASE) 4.5 MG (SALT) PROLONGED RELEASE

How to apply Neupro (III) 7 8 9 n Apply the sticky surface of the patch to the skin n Press the sticky side of the patch firmly into place n Remove the other side of the protective liner using the exposed tab on the liner n Press down the patch firmly with the palm of the hand for about 20 30 seconds

Rotigotine application When using your patches, follow the instructions in the leaflet provided with your patches carefully. One patch: should be applied daily at about the same time each day. patch should be applied to clean, dry, hairless, healthy skin on the lower back, abdomen, hip, shoulder, upper arm or thighs. It is important the sticky side of the patch is not touched. The patch should be pressed down firmly with the palm of the hand for about one minute to make sure it stays in place. Do not apply it to skin that is red, irritated or damaged. Don t apply lotions, creams or powders to the skin before applying the patch, as they will prevent it sticking properly. When changing the patch, the old patch should be removed and disposed of safely; the new patch should be applied to a different area of the skin. It is recommended that the site of application is rotated and that the same site is not used within 14 days of the last application.

APO-go Pump, with syringe and line

IMPULSE CONTROL DISORDER Counsel patients GAMBLING COMPULSIVE BEHAVIOUR HYPERSEXUALITY

MAO-B inhibitors Monamine oxidase type B Make better use of your dopamine by blocking the enzyme called monamine oxidase type B, which breaks down dopamine in brain. RASAGALINE (Azilect) Not SMC approved. 1mg daily SELEGILINE / Eldepryl: 5/10mg tab» Max 10mg

GLUTAMATE ANTAGONIST Not clear exactly how it works AMANTADINE 100-400mg tablets Available in liquid form Used to treat dyskinesia

Avoid the following drugs ANTI-EMETICS: metoclopramide prochlorperazine. ANTI-PSYCHOTICS: fluphenazine trifluorophenazine haloperidol chlorpromazine flupentixol Zuclopenthixol

ANTI-CHOLINERGICS Block acetylcholine which helps send messages from nerves to muscles. Trihexyphenidyl (Benzhexol) Orphenadrine (Disipal) Should not be stopped suddenly unless necessary

In hospital

QUESTION TIME

QUESTIONS (at) Timing of medication; how to deal with taking it late? Why do my co-beneldopa capsules sometimes fail to work entirely, or take a very long time before they have any effect and then only for a very short time?

QUESTIONS (as) Effect of mealtimes and drug dosage (especially protein)

QUESTIONS (ad) What exactly are the benefits of exercise? Does it actually affect movement and medication or is it intended to combat depression?

Does it affect movement Regular exercise helps maintenance of your abilities Strengthens muscles. Increases mobility in joints. Builds up your general fitness and health.

And medication Exercise releases endorphins the" feel good hormones. Boosts energy levels. Helps combat constipation which can interfere with the absorption and effectiveness of medication

Or is it intended to combat depression? Exercise Improves mood. Alleviates stress Improves sleep quality Increases mental focus Increases self esteem

Research on PD and exercise Exercise studies of animal models of PD seems to improve the function of nerve cells and the potential of increased survival of nerve cells within the affected area of the brain.

Research projects on PwP ArgentinianTango balance Wii fit Weight training- Tai chi Flexibility classes Recent studies have shown improvements to Strength balance,coordination,flexibility

QUESTIONS (at) We now have the option of patches for delivering our medication. Could you outline the pro s & cons? Please discuss the Pro s & cons of Rotigotine patches, physical problems, side effects etc and is there an easier alternative?

QUESTIONS (all) Non motor side effects such as confusion and impulse control. A second possible area of discussion are we anywhere near understanding why some people cannot tolerate,or cannot tolerate higher dosage, drugs which others find very helpful in conjunction with levodopa.